Neurturin molecules
AssigneeNTF Therapeutics, Inc.
InventorsPia Runeberg-Roos, Maxim M. Bespalov, Richard Penn, Mart Saarma
Life of this patent
Estimating the term…
Abstract
Neurturin polypeptides which possess reduced heparin and heparan sulfate binding affinity but retain neurotrophic activity, nucleic acids which encode the neurturin variants and vectors and host cells which express the enhanced neurturin polypeptides. Use of the enhanced neurturin polypeptides, nucleic acids and host cells in the treatment or prevention of disease.
Claims29
-37. (canceled)
A method of treating cellular degeneration or insufficiency, comprising administering to a patient in need of such treatment a therapeutically effective amount of a neurturin variant,
- wherein said neurturin variant differs from mature wild type neurturin (SEQ ID NO:5) only by at least one mutation of a positively charged amino acid in the region from amino acid 51 to amino acid 63 of said mature wild type neurturin, and
- wherein said neurturin variant has a decreased affinity to heparin compared to that of mature wild type neurturin.
A method of treating Parkinson's disease, comprising administering to a patient in need of such treatment a therapeutically effective amount of a neurturin variant having the amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:4.
A method of treating Parkinson's disease, comprising administering to a patient in need of such treatment a therapeutically effective amount of a neurturin variant having the amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:4,
- wherein said neurturin variant is administered brain intraparenchymally by direct stereotactic injection or infusion.
Dependencies are inferred from the claim text.